Literature DB >> 21051272

The effect of levodopa dose and body weight on dyskinesia in a prevalent population of people with Parkinson's disease.

Richard W Walker1, Anna R Howells, William K Gray.   

Abstract

AIMS AND
OBJECTIVES: We aimed to investigate the effect of active dose and dose per kilogram (kg) of body weight of levodopa on the occurrence of dyskinesia within a prevalent population of people with PD.
METHODS: Of 106 prevalent cases, 75 (70.8%; 38 males, 37 females) agreed to assessment by a member of the research team. Demographic information, weight and height were recorded. Patients were assessed using a range of rating scales including the Unified Parkinson's Disease Rating Scale. Patients were asked specifically: 'Do you have, or have you ever had, dyskinesia?'.
RESULTS: Nine patients (12.0%) reported dyskinesia. Patient reported dyskinesia was significantly associated with greater years since diagnosis (r=0.309, p=0.007), higher levodopa equivalent dose (r=0.406, p<0.001) and levodopa equivalent dose per kg body weight (r=0.375, p<0.001). Using logistic regression, active levodopa dose, unadjusted for body weight, was an independent predictor of dyskinesia.
CONCLUSIONS: Adjusting levodopa dose for body weight did not increase its degree of correlation with patient reported dyskinesia.
© 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21051272     DOI: 10.1016/j.parkreldis.2010.10.005

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  3 in total

1.  Measures of impulsivity in Parkinson's disease decrease after DBS in the setting of stable dopamine therapy.

Authors:  P Justin Rossi; Sol De Jesus; Christopher W Hess; Daniel Martinez-Ramirez; Kelly D Foote; Aysegul Gunduz; Michael S Okun
Journal:  Parkinsonism Relat Disord       Date:  2017-08-09       Impact factor: 4.891

Review 2.  [Pharmacological treatment of motor symptoms in Parkinson's diseases].

Authors:  W H Jost
Journal:  Nervenarzt       Date:  2017-04       Impact factor: 1.214

3.  The Comparative Efficacy of Non-ergot Dopamine Agonist and Potential Risk Factors for Motor Complications and Side Effects From NEDA Use in Early Parkinson's Disease: Evidence From Clinical Trials.

Authors:  Chunxiao Wu; Hongji Guo; Yingshan Xu; Luping Li; Xinyu Li; Chunzhi Tang; Dongfeng Chen; Meiling Zhu
Journal:  Front Aging Neurosci       Date:  2022-04-22       Impact factor: 5.750

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.